Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinghuatanshi decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Shuguang Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is specifically formulated for the treatment of non-puerperal mastitis (NPM), including plasma cell mastitis (PCM) and granulomatous lobular mastitis (GLM). The decoction is designed to address the TCM patterns of heat-toxicity and phlegm-dampness, which are believed to underlie the chronic inflammatory and nodular nature of these conditions. Mechanistically, the formula exerts anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). Clinical studies conducted at Shuguang Hospital suggest that the decoction can effectively reduce breast mass size, alleviate pain, and lower the risk of post-surgical recurrence in patients with chronic mastitis by modulating the local immune environment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qinghuatanshi decoction.